Top 5 AI-Powered Biotech Stocks to Buy Right Now

We recently compiled a list of the top 5 AI-powered biotech stocks to buy right now. If you want to see the full list and want to know how we came up with these stocks, visit Top 10 AI-Powered Biotech Stocks to Buy Right Now.

5. Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Number of Hedge Fund Holders: 39

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the best biotech stocks.

TheFly reported on April 13 that KYMR announced that the U.S. Food and Drug Administration granted Fast Track designation to KT-621, its first-in-class oral STAT6 degrader being developed for moderate to severe eosinophilic asthma. The investigational once-daily oral therapy is currently in ongoing Phase 2b clinical studies evaluating its potential in asthma and other Type 2 inflammatory conditions.

Early clinical and preclinical data have shown reductions in key inflammatory biomarkers and improvements in disease control measures, supporting its mechanism of action. The designation is intended to facilitate closer regulatory engagement and may help accelerate development timelines for the program as it advances toward later-stage trials.

Further reinforcing the company’s operational momentum, on April 9, Gilead Sciences exercised its option under a collaboration agreement to obtain exclusive global rights to KT-200, a first-in-class oral CDK2 molecular glue degrader developed by Kymera Therapeutics, Inc. (NASDAQ:KYMR). The decision advances the program toward IND-enabling studies, with a planned IND filing targeted for 2027.

As part of the transaction, KYMR is set to receive a $45 million milestone payment and remains eligible for additional future milestone payments and tiered royalties on potential commercial sales. KT-200 is designed to selectively degrade CDK2, a key driver of tumor growth, offering a differentiated approach for cancers driven by CCNE1 alterations, supported by strong preclinical activity and a favorable safety profile.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is an AI-driven biotechnology company developing targeted protein degradation therapies for cancer and immune-inflammatory diseases. It uses computational drug discovery to design small-molecule drugs that eliminate disease-causing proteins instead of inhibiting them.